LB Pharmaceuticals
NEW YORK, NY · Healthcare, Health Care · 21 employees
LB Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of schizophrenia. Our lead drug candidate is a second-generation antipsychotic and a potential first-in-class benzamide to enter the U.S. market. With robust clinical development underway and a focus on long-term patient outcomes, we aim to set a new standard of care for neuropsychiatric co
Funding history
- Funding Round — $285.0M — Sep 2025
- Funding Round — $110.7M — Jan 2024
- Funding Round — $70.7M — Sep 2023
- Funding Round — $16.6M — Nov 2022
- Funding Round — $6.9M — Nov 2022
Recent signals
- Nov 12, 2025: LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer
- Nov 12, 2025: SEC 8-K (5.02): On November 12, 2025, LB Pharmaceuticals Inc announced the appointment of Kaya Pai Panandiker as the Chief Commercial Officer, effective from November 10, 2025. Ms. Panandiker, who is 49 years old, previously held the same position at Neumora Therapeutics and has extensive experience in the field, having also worked at Cerevel Therapeutics and H. Lundbeck. As part of her employment inducement, the Company plans to grant her an equity award, which will be governed by the terms of its 2025 Equity Incentive Plan. This change in leadership is expected to enhance the Company's commercial strategies in line with its growth objectives.
- Sep 11, 2025: Raised $285.0M
- Jan 10, 2024: Raised $110.7M
- Sep 21, 2023: Raised $70.7M
- Nov 23, 2022: Raised $16.6M
- Nov 01, 2022: Raised $6.9M
- Jul 06, 2022: Raised $903K in Series seed
See plans & pricing → Track LB Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.